Innate Pharma: Jumps on EMA boost for experimental blood cancer drug

Innate Pharma SA

13/11/2020 13:13

** U.S.-listed shares  IPHA.O  of France-based drugmaker
rise 13% to more than two-month high of $4.82 premarket
    ** IPHA says European Medicines Agency (EMA) has granted
PRIME designation to company's experimental drug, lacutamab, for
treating patients with relapsed or refractory Sézary syndrome
(SS), who have received prior therapies  urn:newsml:reuters.com:*:nGNE6hY9zK
    ** SS is an aggressive form of cutaneous T-cell lymphoma,
which occurs when T-cells, a type of white blood cell, become
cancerous and affect the skin
    ** PRIME designation allows for proactive support from EMA
throughout the clinical development process and enables
accelerated assessment
    ** Lacutamab got fast-track designation for SS from U.S. FDA
in 2019 (https://bit.ly/3eWlBp1)
    ** Up to Thursday's close, shares down 33.9% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com))